Skip to main content
$115.23 $0.23 (0.2%)

10:34 AM EST on 01/22/21

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

CAPS Rating: 4 out of 5

Discovers, develops and intend to commercialize drugs for the treatment of neurological and endocrine-related diseases and disorders. Product candidates will target insomnia, anxiety, depression, cancer, diabetes, and multiple sclerosis.

Current Price $115.23 Mkt Cap $10.7B
Open $115.33 P/E Ratio 114.28
Prev. Close $115.00 Div. (Yield) $0.00 (0.0%)
Daily Range $114.09 - $115.50 Volume 119,691
52-Wk Range $72.14 - $136.27 Avg. Daily Vol. 865,769

Caps

How do you think NASDAQ:NBIX will perform against the market?

Add Stock to CAPS Watchlist

All Players

438 Outperform
45 Underperform
 

All-Star Players

148 Outperform
4 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NBIX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Itsnottoolate (99.04)
Submitted October 04, 2020

NBIX is ow non sale just as the company is ready to begin marketing Ongentys as COVID-19 restrictions ease. There could be significant demand for thIS drug because roughly 70% of the 1 million Americans with Parkinson's disease currently take… More

zzlangerhans (95.47)
Submitted September 10, 2012

Neurocrine has been turning in solid pipeline progress for several years now but they haven't had much success holding gains in the share price. Now that the phase III trial of elagolix is in progress I expect at least a year before all 875 patients… More

NASDAQ:NBIX VS S&P 500 (SPY)

Fools bullish on NASDAQ:NBIX are also bullish on:

Fools bearish on NASDAQ:NBIX are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about NBIX.

Recs

0
Member Avatar jjhegi (74.09) Submitted: 12/12/2020 9:23:03 PM : Outperform Start Price: $117.21 NASDAQ:NBIX Score: -10.82

Skyrocketing revenues, no long-term debt, loads of cash. strong free cash flow, CEO owns lots of stock.

Recs

1
Member Avatar Itsnottoolate (99.04) Submitted: 10/3/2020 8:36:33 PM : Outperform Start Price: $95.13 NASDAQ:NBIX Score: +7.09

NBIX is ow non sale just as the company is ready to begin marketing Ongentys as COVID-19 restrictions ease.

There could be significant demand for thIS drug because roughly 70% of the 1 million Americans with Parkinson's disease currently take levodopa which to my understanding this is going to disrupt.

Recs

0
Member Avatar ak0730 (< 20) Submitted: 9/26/2020 9:24:26 PM : Outperform Start Price: $96.68 NASDAQ:NBIX Score: +4.18

Great pipleline and available for a discount below $100

Leaderboard

Find the members with the highest scoring picks in NBIX.

Score Leader

gsm1999

gsm1999 (61.84) Score: +4,665.29

The Score Leader is the player with the highest score across all their picks in NBIX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
gsm1999 61.84 3/8/2010 Outperform 5Y $2.30 +4,900.00% +234.71% +4,665.29 0 Comment
awsumrocker 81.92 3/10/2010 Outperform 3M $2.35 +4,793.62% +233.98% +4,559.64 0 Comment
stockamuteur 60.75 4/8/2010 Outperform 5Y $2.57 +4,374.71% +224.24% +4,150.47 0 Comment
Tadpole85 61.50 1/5/2010 Outperform 1Y $2.68 +4,191.04% +237.67% +3,953.38 0 Comment
borcobob 75.56 12/28/2009 Outperform 3Y $2.82 +3,978.01% +238.74% +3,739.27 0 Comment
royeknox 68.09 8/10/2009 Outperform 5Y $3.03 +3,695.38% +281.56% +3,413.82 0 Comment
MicroOptions 59.29 4/15/2010 Outperform 5Y $3.10 +3,609.68% +216.09% +3,393.58 0 Comment
MicroMikey 42.76 4/15/2010 Outperform 5Y $3.10 +3,609.68% +216.09% +3,393.58 0 Comment
minifesto 76.84 1/2/2009 Outperform 3Y $3.21 +3,482.55% +330.32% +3,152.23 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. foolshand < 20 7/27/2009 Outperform 3W $3.25 +3,438.46% +292.56% +3,145.90 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NBIX.